Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 4
2005 2
2006 6
2007 8
2008 12
2009 7
2010 8
2011 10
2012 8
2013 12
2014 22
2015 14
2016 8
2017 11
2018 9
2019 12
2020 16
2021 9
2022 13
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Clinical Trial.
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
Wada T, Hibino M, Aono H, Kyoda S, Iwadate Y, Shishido E, Ikeda K, Kinoshita N, Matsuda Y, Otani S, Kameda R, Matoba K, Nonaka M, Maeda M, Kumagai Y, Ako J, Shichiri M, Naoki K, Katagiri M, Takaso M, Iwamura M, Katayama K, Miyatsuka T, Orihashi Y, Yamaoka K; CORVETTE-01 Study Group. Wada T, et al. Among authors: iwamura m. Front Med (Lausanne). 2023 May 22;10:1139046. doi: 10.3389/fmed.2023.1139046. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37283627 Free PMC article.
Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.
Kawahara T, Saigusa Y, Yoneyama S, Kato M, Kojima I, Yamada H, Kamihira O, Tabata K, Tsumura H, Iwamura M, Makiyama K, Uemura H, Miyoshi Y. Kawahara T, et al. Among authors: iwamura m. BMC Cancer. 2023 Mar 7;23(1):214. doi: 10.1186/s12885-023-10700-0. BMC Cancer. 2023. PMID: 36882764 Free PMC article.
Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study.
Tachibana T, Ikeda M, Shimura S, Amano N, Murakami Y, Yamada Y, Koguchi D, Maeyama R, Kawamura M, Sakata Y, Hagiwara M, Matsumoto K, Iwamura M. Tachibana T, et al. Among authors: iwamura m. Urol Int. 2023;107(3):230-238. doi: 10.1159/000527718. Epub 2023 Jan 16. Urol Int. 2023. PMID: 36646046 Free PMC article.
Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.
Koguchi D, Matsumoto K, Ikeda M, Shimizu Y, Nakamura M, Shiono Y, Katsumata H, Sato Y, Iwamura M. Koguchi D, et al. Among authors: iwamura m. Int J Mol Sci. 2022 Oct 11;23(20):12119. doi: 10.3390/ijms232012119. Int J Mol Sci. 2022. PMID: 36292976 Free PMC article.
188 results